# Clinical Trials Data EGFR - Document 44

# Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT00353717

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with metastatic breast carcinoma of the basal like subtype with available biopsy for analysis and ECOG PS of 2 or less\n\nExclusion Criteria:\n\n\* Pregnancy\n\* BUN, blood creatinine, AST, ALT \\> X3 of upper limits of normal\n\* More than previous 2 chemotherapy lines in the metastatic settings or the use of previous inhibitors of EGFR",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
No. The patient having an EGFR mutation would be excluded because the criteria specifically excludes patients who have received "previous inhibitors of EGFR". While EGFR mutations are common in \*lung\* cancer and often treated with EGFR inhibitors, this trial is for \*breast\* cancer, and prior use of EGFR inhibitors disqualifies a patient.